A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma

• Status: RECRUITING
• Trial end date: 2027-05-31

Summary

Evaluation of the safety and tolerability of immune-targeted therapy combined with neoadjuvant therapy with lysogenic HSV virus for patients with surgically resectable squamous carcinoma of the head and neck.

• Phase: PHASE1

Details

• Lead Sponsor: West China Hospital
• Treatments: Afatinib; Biological Factors; Immunotherapy; tislelizumab